Kalaris Therapeutics, Inc., a clinical-stage ophthalmology biotech company, engages in developing therapies for the treatment of neovascular retinal diseases. Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeutics, Inc. in May 2024. The company was incorporated in 2019 and is based in Palo Alto, California. Show more

Location: 628 Middlefield Road, Palo Alto, CA, 94301, United States | Website: https://kalaristx.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

46.01M

52 Wk Range

$2.28 - $24.15

Previous Close

$2.46

Open

$2.43

Volume

203,565

Day Range

$2.35 - $2.52

Enterprise Value

-51.03M

Cash

101M

Avg Qtr Burn

-5.898M

Insider Ownership

17.19%

Institutional Own.

70.34%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date